Morgan Stanley notes that CMS released the 2024 Final Medicare Advantage rate notice on Friday afternoon and that the firm sees the final 2024 rates as 115 basis points better than the Advance notice. This compares to the firm’s base case for a 50-100 point rate improvement, which believes the favorable outcome could drive Humana shares to potentially trade up by a mid-single digit percentage on Monday. The firm keeps an Overweight rating on Humana shares, which are up $16.72, or 3%, to $502.18 in pre-market trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HUM:
- Final Medicare Advantage rates positive for managed care, says JPMorgan
- Ohio AG Yost sues Express Scripts, Prime Therapeutics over drug price fixing
- Cigna, Humana accused of price fixing by Ohio attorney general, WSJ reports
- Humana stock a bet on healthcare for seniors, Barron’s says
- Humana Foundation Board of Directors elects Jones as Chairman